Integrating cancer genomic data into electronic health records

Genome Medicine

Volumn 8, Issue 1, 2016, Pages

  Warner, Jeremy L ^a,b,c   Jain, Sandeep K ^b,d   Levy, Mia A ^a,b,c  

^a VANDERBILT UNIVERSITY   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^c VANDERBILT INGRAM CANCER CENTER   (United States)

^d VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIRCULATING CELL FREE TUMOR DNA; DNA; GEFITINIB; IMATINIB; OSIMERTINIB; PONATINIB; ROCILETINIB; UNCLASSIFIED DRUG; VEMURAFENIB;

BIOINFORMATICS; CANCER DIAGNOSIS; CANCER IMMUNOTHERAPY; CANCER PREVENTION; CANCER PROGNOSIS; CHRONIC MYELOID LEUKEMIA; DNA METHYLATION; DNA SEQUENCE; ELECTRONIC HEALTH RECORD; FLOW CYTOMETRY; FLUORESCENCE IN SITU HYBRIDIZATION; GASTROINTESTINAL STROMAL TUMOR; GENE EXPRESSION; GENOMICS; HUMAN; IMMUNOHISTOCHEMISTRY; INFORMATION PROCESSING; KNOWLEDGE BASE; LUNG ADENOCARCINOMA; MASS CYTOMETRY; MELANOMA; MIDDLEWARE; MONITORING; NEXT GENERATION SEQUENCING; NON SMALL CELL LUNG CANCER; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REVIEW; SEQUENCE ANALYSIS; STANDARD; WHOLE EXOME SEQUENCING; WHOLE GENOME SEQUENCING; CLINICAL DECISION SUPPORT SYSTEM; ELECTRONIC MEDICAL RECORD SYSTEM; GENETICS; MEDICAL INFORMATICS; MEDICAL INFORMATION SYSTEM; NEOPLASMS; ONCOLOGY; PROCEDURES; STATISTICS AND NUMERICAL DATA; SYSTEM ANALYSIS;

DECISION SUPPORT SYSTEMS, CLINICAL; ELECTRONIC HEALTH RECORDS; GENOMICS; HEALTH INFORMATION SYSTEMS; HUMANS; MEDICAL INFORMATICS; MEDICAL ONCOLOGY; MEDICAL RECORDS SYSTEMS, COMPUTERIZED; NEOPLASMS; SYSTEMS INTEGRATION;

EID: 84992463448     PISSN: None     EISSN: 1756994X     Source Type: Journal    
DOI: 10.1186/s13073-016-0371-3     Document Type: Review

References (122)

1. Stratton MR. Exploring the genomes of cancer cells: progress and promise. Science. 2011;331:1553-8.
2. Stratton MR, Campbell PJ, Futreal PA. The cancer genome. Nature. 2009;458:719-24.
3. Garraway LA, Lander ES. Lessons from the cancer genome. Cell. 2013;153:17-37.
4. Van Allen EM, Wagle N, Levy MA. Clinical analysis and interpretation of cancer genome data. J Clin Oncol. 2013;31:1825-33.
5. Weed LL. Medical records that guide and teach. N Engl J Med. 1968;278:593-600.
6. Kuhn T, Basch P, Barr M, Yackel T, Medical Informatics Committee of the American College of Physicians. Clinical documentation in the 21st century: executive summary of a policy position paper from the American College of Physicians. Ann Intern Med. 2015;162:301-3.
7. Stewart BW, Bray F, Forman D, Ohgaki H, Straif K, Ullrich A, et al. Cancer prevention as part of precision medicine: "plenty to be done.". Carcinogenesis. 2016;37:2-9.
8. Collins FS, Varmus H. A new initiative on precision medicine. N Engl J Med. 2015;372:793-5.
9. Kensler TW, Spira A, Garber JE, Szabo E, Lee JJ, Dong Z, et al. Transforming Cancer Prevention through Precision Medicine and Immune-oncology. Cancer Prev Res (Phila). 2016;9:2-10.
10. Nielsen TO, West RB, Linn SC, Alter O, Knowling MA, O'Connell JX, et al. Molecular characterisation of soft tissue tumours: a gene expression study. Lancet. 2002;359:1301-7.
11. Konstantinopoulos PA, Fountzilas E, Goldsmith JD, Bhasin M, Pillay K, Francoeur N, et al. Analysis of multiple sarcoma expression datasets: implications for classification, oncogenic pathway activation and chemotherapy resistance. PLoS One. 2010;5:e9747.
12. Varadhachary GR, Raber MN. Cancer of unknown primary site. N Engl J Med. 2014;371:757-65.
13. Konstantinopoulos PA, Spentzos D, Karlan BY, Taniguchi T, Fountzilas E, Francoeur N, et al. Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer. J Clin Oncol. 2010;28:3555-61.
14. Den Boer ML, van Slegtenhorst M, De Menezes RX, Cheok MH, Buijs-Gladdines JGCAM, Peters STCJM, et al. A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study. Lancet Oncol. 2009;10:125-34.
15. Edge S, Byrd D, Compton C, Fritz A, Greene F, Trotti A, York S, editors. AJCC Cancer Staging Manual | Stephen Edge | Springer. In: Springer.com. http://www.springer.com/us/book/9780387884400. Accessed 31 Aug 2016.
16. Ford CE, Jacobs PA, Lajtha LG. Human somatic chromosomes. Nature. 1958;181:1565-8.
17. Baikie AG, Brown WM, Jacobs PA, Milne JS. Chromosome studies in human leukaemia. Lancet. 1959;2:425-8.
18. Hart JS, Trujillo JM, Freireich EJ, George SL, Frei E. Cytogenetic studies and their clinical correlates in adults with acute leukemia. Ann Intern Med. 1971;75:353-60.
19. Mullighan CG, Su X, Zhang J, Radtke I, Phillips LAA, Miller CB, et al. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med. 2009;360:470-80.
20. Kris MG, Natale RB, Herbst RS, Lynch TJ, Prager D, Belani CP, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA. 2003;290:2149-58.
21. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350:2129-39.
22. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361:947-57.
23. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med. 1996;2:561-6.
24. Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002;347:472-80.
25. Johnson DB, Estrada MV, Salgado R, Sanchez V, Doxie DB, Opalenik SR, et al. Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy. Nat Commun. 2016;7:10582.
26. Bower H, Björkholm M, Dickman PW, Höglund M, Lambert PC, Andersson TM-L. Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population. J Clin Oncol. 2016;34:2851-7.
27. Roychowdhury S, Chinnaiyan AM. Translating genomics for precision cancer medicine. Annu Rev Genomics Hum Genet. 2014;15:407.
28. Deininger MW. Diagnosing and managing advanced chronic myeloid leukemia. Am Soc Clin Oncol Educ Book. 2015;e381-8. doi: 10.14694/EdBook_AM.2015.35.e381.
29. Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391-405.
30. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228-47.
31. Soverini S, Colarossi S, Gnani A, Rosti G, Castagnetti F, Poerio A, et al. Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia. Clin Cancer Res. 2006;12:7374-9.
32. Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, Zakowski MF, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2005;2:e73.
33. Cortes JE, Kim D-W, Pinilla-Ibarz J, le Coutre P, Paquette R, Chuah C, et al. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med. 2013;369:1783-96.
34. Jänne PA, Yang JC-H, Kim D-W, Planchard D, Ohe Y, Ramalingam SS, et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med. 2015;372:1689-99.
35. Sequist LV, Soria J-C, Goldman JW, Wakelee HA, Gadgeel SM, Varga A, et al. Rociletinib in EGFR-mutated non-small-cell lung cancer. N Engl J Med. 2015;372:1700-9.
36. Johnson DB, Menzies AM, Zimmer L, Eroglu Z, Ye F, Zhao S, et al. Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms. Eur J Cancer. 2015;51:2792-9.
37. Abrams J, Conley B, Mooney M, Zwiebel J, Chen A, Welch JJ, et al. National Cancer Institute's Precision Medicine Initiatives for the new National Clinical Trials Network. Am Soc Clin Oncol Educ Book. 2014;71-6. doi: 10.14694/EdBook_AM.2014.34.71.
38. Pyo J-S, Kang G, Sohn JH. ALK immunohistochemistry for ALK gene rearrangement screening in non-small cell lung cancer: a systematic review and meta-analysis. Int J Biol Markers. 2016.
39. Ibrahim SF, van den Engh G. Flow cytometry and cell sorting. Adv Biochem Eng Biotechnol. 2007;106:19-39.
40. Macintyre G, Ylstra B, Brenton JD. Sequencing Structural Variants in Cancer for Precision Therapeutics. Trends Genet. 2016;32:530-42.
41. Singh RR, Mehrotra M, Chen H, Almohammedsalim AA, Sahin A, Bosamra A, et al. Comprehensive Screening of gene copy number aberrations in formalin-fixed, paraffin-embedded solid tumors using molecular inversion probe-based single-nucleotide polymorphism array. J Mol Diagn. 2016;18:676-87.
42. Su Z, Dias-Santagata D, Duke M, Hutchinson K, Lin YL, Borger DR, et al. A platform for rapid detection of multiple oncogenic mutations with relevance to targeted therapy in non-small-cell lung cancer. J Mol Diagn. 2011;13:74-84.
43. Hunter DJ. Uncertainty in the Era of Precision Medicine. N Engl J Med. 2016;375:711-3.
44. van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AAM, Voskuil DW, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002;347:1999-2009.
45. Goodwin S, McPherson JD, McCombie WR. Coming of age: ten years of next-generation sequencing technologies. Nat Rev Genet. 2016;17:333-51.
46. Warr A, Robert C, Hume D, Archibald A, Deeb N, Watson M. Exome Sequencing: Current and Future Perspectives. G3. 2015;5:1543-50.
47. Ng PC, Kirkness EF. Whole genome sequencing. Methods Mol Biol. 2010;628:215-26.
48. Chabanon RM, Pedrero M, Lefebvre C, Marabelle A, Soria J-C, Postel-Vinay S. Mutational Landscape and sensitivity to immune checkpoint blockers. Clin Cancer Res. 2016;22:4309-21.
49. Campesato LF, Barroso-Sousa R, Jimenez L, Correa BR, Sabbaga J, Hoff PM, et al. Comprehensive cancer-gene panels can be used to estimate mutational load and predict clinical benefit to PD-1 blockade in clinical practice. Oncotarget. 2015;6:34221-7.
50. Garofalo A, Sholl L, Reardon B, Taylor-Weiner A, Amin-Mansour A, Miao D, et al. The impact of tumor profiling approaches and genomic data strategies for cancer precision medicine. Genome Med. 2016;8:79.
51. Tarczy-Hornoch P, Amendola L, Aronson SJ, Garraway L, Gray S, Grundmeier RW, et al. A survey of informatics approaches to whole-exome and whole-genome clinical reporting in the electronic health record. Genet Med. 2013;15:824-32.
52. Schwaederle M, Husain H, Fanta PT, Piccioni DE, Kesari S, Schwab RB, et al. Use of Liquid Biopsies in Clinical Oncology: Pilot Experience in 168 Patients. Clin Cancer Res. 2016.
53. Aparicio S, Caldas C. The implications of clonal genome evolution for cancer medicine. N Engl J Med. 2013;368:842-51.
54. Shi H, Hugo W, Kong X, Hong A, Koya RC, Moriceau G, et al. Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. Cancer Discov. 2014;4:80-93.
55. de Matos LL, Trufelli DC, de Matos MGL, da Silva Pinhal MA. Immunohistochemistry as an important tool in biomarkers detection and clinical practice. Biomark Insights. 2010;5:9-20.
56. Mora J, Given Chunyk A, Dysinger M, Purushothama S, Ricks C, Osterlund K, et al. Next generation ligand binding assays-review of emerging technologies' capabilities to enhance throughput and multiplexing. AAPS J. 2014;16:1175-84.
57. Han L, Qiu P, Zeng Z, Jorgensen JL, Mak DH, Burks JK, et al. Single-cell mass cytometry reveals intracellular survival/proliferative signaling in FLT3-ITD-mutated AML stem/progenitor cells. Cytometry A. 2015;87:346-56.
58. Laird PW. The power and the promise of DNA methylation markers. Nat Rev Cancer. 2003;3:253-66.
59. Blumenthal D. Launching HITECH. N Engl J Med. 2010;362:382-5.
60. Blumenthal D, Tavenner M. The "meaningful use" regulation for electronic health records. N Engl J Med. 2010;363:501-4.
61. Ford EW, Menachemi N, Phillips MT. Predicting the adoption of electronic health records by physicians: when will health care be paperless? J Am Med Inform Assoc. 2006;13:106-12.
62. Hoffman MA. The genome-enabled electronic medical record. J Biomed Inform. 2007;40:44-6.
63. Louie B, Mork P, Martin-Sanchez F, Halevy A, Tarczy-Hornoch P. Data integration and genomic medicine. J Biomed Inform. 2007;40:5-16.
64. Shabo A. The implications of electronic health records for personalized medicine. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2005;149:251-8.
65. Kho AN, Rasmussen LV, Connolly JJ, Peissig PL, Starren J, Hakonarson H, et al. Practical challenges in integrating genomic data into the electronic health record. Genet Med. 2013;15:772-8.
66. Valencia A, Hidalgo M. Getting personalized cancer genome analysis into the clinic: the challenges in bioinformatics. Genome Med. 2012;4:61.
67. Gray PN, Dunlop CLM, Elliott AM. Not all next generation sequencing diagnostics are created equal: understanding the nuances of solid tumor assay design for somatic mutation detection. Cancers (Basel). 2015;7:1313-32.
68. Manrai AK, Funke BH, Rehm HL, Olesen MS, Maron BA, Szolovits P, et al. Genetic misdiagnoses and the potential for health disparities. N Engl J Med. 2016;375:655-65.
69. Schrader KA, Cheng DT, Joseph V, Prasad M, Walsh M, Zehir A, et al. Germline variants in targeted tumor sequencing using matched normal DNA. JAMA Oncol. 2016;2:104-11.
70. Jones S, Anagnostou V, Lytle K, Parpart-Li S, Nesselbush M, Riley DR, et al. Personalized genomic analyses for cancer mutation discovery and interpretation. Sci Transl Med. 2015;7:283ra53.
71. Roh MR, Eliades P, Gupta S, Tsao H. Genetics of melanocytic nevi. Pigment Cell Melanoma Res. 2015;28:661-72.
72. 1000 Genomes Project Consortium, Abecasis GR, Altshuler D, Auton A, Brooks LD, Durbin RM, et al. A map of human genome variation from population-scale sequencing. Nature. 2010;467:1061-73.
73. Lek M, Karczewski KJ, Minikel EV, Samocha KE, Banks E, Fennell T, et al. Analysis of protein-coding genetic variation in 60,706 humans. Nature. 2016;536:285-91.
74. Kehr B, Trappe K, Holtgrewe M, Reinert K. Genome alignment with graph data structures: a comparison. BMC Bioinforma. 2014;15:99.
75. ga4gh/schemas. In: GitHub. 2016. http://github.com/ga4gh/schemas. Accessed 31 Aug 2016.
76. Precision Medicine Initiative. In: Fda.gov. 2016. http://www.fda.gov/ScienceResearch/SpecialTopics/PrecisionMedicine/default.htm. Accessed 2 Oct 2016.
77. Gargis AS, Kalman L, Bick DP, da Silva C, Dimmock DP, Funke BH, et al. Good laboratory practice for clinical next-generation sequencing informatics pipelines. Nat Biotechnol. 2015;33:689-93.
78. Wadsworth Center. Laws & Regulations. In: New York State Department of Health, Wadsworth Center. 2016. http://www.wadsworth.org/regulatory/clep/laws. Accessed 2 Oct 2016.
79. Rehm HL, Bale SJ, Bayrak-Toydemir P, Berg JS, Brown KK, Deignan JL, et al. ACMG clinical laboratory standards for next-generation sequencing. Genet Med. 2013;15:733-47.
80. Kandoth C, McLellan MD, Vandin F, Ye K, Niu B, Lu C, et al. Mutational landscape and significance across 12 major cancer types. Nature. 2013;502:333-9.
81. Lawrence MS, Stojanov P, Polak P, Kryukov GV, Cibulskis K, Sivachenko A, et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature. 2013;499:214-8.
82. Lawrence MS, Stojanov P, Mermel CH, Robinson JT, Garraway LA, Golub TR, et al. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature. 2014;505:495-501.
83. GenomeWeb. Quest, Athena Reply to Plaintiffs in Wrongful Death Lawsuit. New York: Genomeweb LLC., GenomeWeb; 2016.
84. Balmaña J, Digiovanni L, Gaddam P, Walsh MF, Joseph V, Stadler ZK, et al. Conflicting interpretation of genetic variants and cancer risk by commercial laboratories as assessed by the prospective registry of multiplex testing. J Clin Oncol. 2016. doi: 10.1200/JCO.2016.68.4316.
85. Shirts BH, Salama JS, Aronson SJ, Chung WK, Gray SW, Hindorff LA, et al. CSER and eMERGE: current and potential state of the display of genetic information in the electronic health record. J Am Med Inform Assoc. 2015;22:1231-42.
86. Ullman-Cullere MH, Mathew JP. Emerging landscape of genomics in the electronic health record for personalized medicine. Hum Mutat. 2011;32:512-6.
87. Gray KA, Yates B, Seal RL, Wright MW, Bruford EA. Genenames.org: the HGNC resources in 2015. Nucleic Acids Res. 2015;43:D1079-85.
88. Horaitis O, Cotton RGH. The challenge of documenting mutation across the genome: the human genome variation society approach. Hum Mutat. 2004;23:447-52.
89. McGowan-Jordan J, Simons A, Schmid M, editors. An International System for Human Cytogenomic Nomenclature (ISCN 2016). 2016.
90. Yu P, Artz D, Warner J. Electronic health records (EHRs): supporting ASCO's vision of cancer care. American Society of Clinical Oncology educational book / ASCO. Am Soc Clin Oncol Meet. 2014;34:225-31.
91. HL7 Standards Product Brief - HL7 version 2 implementation guide: clinical genomics; fully LOINC-qualified genetic variation model (US Realm). In: Hl7.org. 2016. http://www.hl7.org/implement/standards/product_brief.cfm?product_id=23. Accessed 31 Aug 2016.
92. Rioth MJ, Staggs DB, Hackett L, Haberman E, Tod M, Levy M, et al. Implementing and improving automated electronic tumor molecular profiling. J Oncol Pract. 2016;12:e332-7.
93. Rioth MJ, Thota R, Staggs DB, Johnson DB, Warner JL. Pragmatic precision oncology: the secondary uses of clinical tumor molecular profiling. J Am Med Inform Assoc. 2016;23:773-6.
94. Welcome to FoundationICE. In: Foundationice.com. 2016. https://foundationice.com/login?url=%2F. Accessed 30 Sept 2016.
95. Caris Molecular Intelligence Service. In: Carismolecularintelligence.com. 2016. http://www.carismolecularintelligence.com/. Accessed 30 Sept 2016.
96. Customers | Syapse. In: Syapse.com. 2016. http://www.syapse.com/customers/. Accessed 30 Sept 2016.
97. Mandl KD, Mandel JC, Kohane IS. Driving innovation in health systems through an apps-based information economy. Cell Syst. 2015;1:8-13.
98. NCI Drug Dictionary. In: National Cancer Institute. 2016. https://www.cancer.gov/publications/dictionaries/cancer-drug. Accessed 30 Sept 2016.
99. (2016) openFDA. In: Open.fda.gov. https://open.fda.gov/. Accessed 30 Sept 2016
100. Mandl KD, Mandel JC, Murphy SN, Bernstam EV, Ramoni RL, Kreda DA, et al. The SMART Platform: early experience enabling substitutable applications for electronic health records. J Am Med Inform Assoc. 2012;19:597-603.
101. Mandel JC, Kreda DA, Mandl KD, Kohane IS, Ramoni RB. SMART on FHIR: a standards-based, interoperable apps platform for electronic health records. J Am Med Inform Assoc. 2016;23(5):899-908.
102. Alterovitz G, Warner J, Zhang P, Chen Y, Ullman-Cullere M, Kreda D, et al. SMART on FHIR Genomics: facilitating standardized clinico-genomic apps. J Am Med Inform Assoc. 2015;22:1173-8.
103. Warner JL, Rioth MJ, Mandl KD, Mandel JC, Kreda DA, Kohane IS, et al. SMART precision cancer medicine: a FHIR-based app to provide genomic information at the point of care. J Am Med Inform Assoc. 2016;23:701-10.
104. FHIR Genomics - Connectathon/Documents. In: Projects.iq.harvard.edu. 2016. http://projects.iq.harvard.edu/fhirgenomics. Accessed 31 Aug 2016.
105. Sync For Science. In: Syncfor.science. 2016. http://syncfor.science/. Accessed 30 Sept 2016.
106. Sync for Science. In: GitHub. 2016. https://github.com/sync-for-science. Accessed 30 Sept 2016.
107. Kaufman DJ, Baker R, Milner LC, Devaney S, Hudson KL. A survey of U.S adults' opinions about conduct of a nationwide Precision Medicine Initiative® cohort study of genes and environment. PLoS One. 2016;11:e0160461.
108. Genetically Informed Cancer Medicine - My Cancer Genome. In: Mycancergenome.org. 2016. https://www.mycancergenome.org/. Accessed 30 Sept 2016.
109. My Cancer Genome: Web-based clinical decision support for genome-directed lung cancer treatment. | 2011 ASCO Annual Meeting | Abstracts | Meeting Library. In: Meetinglibrary.asco.org. 2016. http://meetinglibrary.asco.org/content/82277-102. Accessed 31 Aug 2016.
110. Taylor AD, Micheel CM, Anderson IA, Levy MA, Lovly CM. The path(way) less traveled: a pathway-oriented approach to providing information about precision cancer medicine on My Cancer Genome. Transl Oncol. 2016;9:163-5.
111. JAX-Clinical Knowledgebase. 2016. https://ckb.jax.org. Accessed 13 Oct 2016.
112. Patterson SE, Liu R, Statz CM, Durkin D, Lakshminarayana A, Mockus SM. The clinical trial landscape in oncology and connectivity of somatic mutational profiles to targeted therapies. Hum Genomics. 2016;10:4.
113. OncoKB. In: Oncokb.org. 2016. http://oncokb.org/#/. Accessed 30 Sept 2016.
114. CIViC - Clinical Interpretations of Variants in Cancer. In: Civic.genome.wustl.edu. 2016. https://civic.genome.wustl.edu/#/about. Accessed 30 Sept 2016.
115. ClinGen - ClinGen | Clinical Genome Resource. In: Clinicalgenome.org. 2016. https://clinicalgenome.org/. Accessed 30 Sept 2016.
116. Rehm HL, Berg JS, Brooks LD, Bustamante CD, Evans JP, Landrum MJ, et al. ClinGen--the Clinical Genome Resource. N Engl J Med. 2015;372:2235-42.
117. Kirkpatrick BE, Riggs ER, Azzariti DR, Miller VR, Ledbetter DH, Miller DT, et al. GenomeConnect: matchmaking between patients, clinical laboratories, and researchers to improve genomic knowledge. Hum Mutat. 2015;36:974-8.
118. API Reference. In: Cds-hooks.org. 2016. http://cds-hooks.org/. Accessed 30 Sept 2016.
119. welcome to eCDS_KB. In: Cdskb.org. 2016. https://cdskb.org/. Accessed 1 Sept 2016.
120. Delbanco T, Walker J, Darer JD, Elmore JG, Feldman HJ, Leveille SG, et al. Open notes: doctors and patients signing on. Ann Intern Med. 2010;153:121-5.
121. Krauss JC, Warner JL, Maddux SE, Brown JR, Moldwin R, Schorer AE, et al. Data sharing to support the cancer journey in the digital era. J Oncol Pract. 2016;12:201-7.
122. DIGITizE: Displaying and Integrating Genetic Information Through the EHR: Health and Medicine Division. In: Nationalacademies.org. 2016. http://www.nationalacademies.org/hmd/Activities/Research/GenomicBasedResearch/Innovation-Collaboratives/EHR.aspx. Accessed 2 Oct 2016.